A total of 31 patients with prostatic adenocarcinoma received a total of 35 half-body irradiation treatments; 13 treatments of 600 to 800 cGy. to the upper half and 22 treatments of 400 to 1,000 cGy. to the lower half of the body. The interval from the discovery of osseous metastases to symptomatic need for half-body irradiation was similar for all tumor grades and stages except for patients with well differentiated lesions, in whom this interval was significantly longer as was survival time after half-body therapy. Treatment was well tolerated and relief of pain was substantial. The majority of the patients obtained subjective relief evidenced by decreased use of narcotic analgesics or change to nonprescription medication. Median survival after half-body irradiation was 5 months. Palliative effects were maintained until death in 82 per cent of the patients treated to the upper and 67 per cent treated to the lower half of the body.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0022-5347(17)40897-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer (POINTER-PC) - study protocol paper for a phase III multicentre, open-label randomised controlled trial.
BMJ Open
December 2024
Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Introduction: Prostate cancer (PCa) is the most common cancer in men. Recurrence may occur in up to half of patients initially treated with curative intent for high-risk localised/locally advanced PCa. Pelvic nodal recurrence is common in this setting, but no clear standard of care exists for these patients, with potential therapeutic approaches including stereotactic body radiotherapy (SBRT) to the involved node(s) alone, extended nodal irradiation (ENI) to treat sites of potential micrometastatic spread in addition to involved node(s) and androgen deprivation therapy with or without additional systemic anticancer therapies.
View Article and Find Full Text PDFBCL11A +58/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques conditioned with a CD45 antibody-drug conjugate.
Cell Stem Cell
December 2024
National Heart, Lung, and Blood Institute (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, MD 20814, USA. Electronic address:
Editing the +58 region of the BCL11A erythroid enhancer has shown promise in treating β-globin disorders. To address variations in fetal hemoglobin (HbF) response, we investigated editing both +58 and +55 enhancers. Rhesus macaques transplanted with edited hematopoietic stem/progenitor cells (HSPCs) following busulfan conditioning exhibited durable, high-level (∼90%) editing frequencies post transplantation with sustained HbF reactivation over 4 years, without hematological perturbations.
View Article and Find Full Text PDFRectal Epithelial Stem Cell Kinetics in Acute Radiation Proctitis.
Int J Mol Sci
October 2024
Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 754-8553, Japan.
The intestinal tract is a typical radiosensitive tissue, and radiation rectal injury is a severe side effect that limits the prescribed dose in radiotherapy of the abdominal and pelvic region. Understanding the post-irradiation kinetics of -positive stem cells is crucial in comprehending this adverse process. In this study, we utilized - knock-in mice expressing EGFP and LGR5 antibody fluorescence staining of wild-type mice.
View Article and Find Full Text PDFHalf body irradiation (HBI) for bone metastases in the modern radiotherapy technique era - A systematic review.
Clin Transl Radiat Oncol
November 2024
Department of Radiotherapy, Medical University of Lodz, Lodz, Poland.
Bone metastases (BMs) are the most common cause of cancer-related pain and radiation therapy plays a key role in treating pain caused by it. The half-body irradiation (HBI) is a modality that can be used to treat patients with multiple painful BMs. In the modern era, concerns about toxicity and the availability of new agents requiring robust bone marrow function have limited the use of HBI in advanced cancer.
View Article and Find Full Text PDFHigh Bioavailability of Spinach Folate Evaluated by Functional Biomarkers in a Folate Depletion-Repletion Mouse Model.
J Nutr Sci Vitaminol (Tokyo)
September 2024
Faculty of Food and Health Sciences, Showa Women's University.
Article Synopsis
- The study examined the bioavailability of folate from spinach compared to synthetic folic acid (FA) in mice, revealing that natural folates like those from spinach have significantly different absorption rates.
- Mice were placed on a folate-deficient diet and then given either synthetic FA or spinach folate to measure how well each source replenished folate levels and affected health markers.
- Results indicated that spinach folate restored folate levels in the body to about 69% of FA levels and showed promising improvements in plasma homocysteine and chromosomal integrity, suggesting that spinach folate is more bioavailable than previously thought.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!